Albuquerque, NM, May 27, 2026 – Indica Labs, the global leader in AI-powered digital pathology solutions, today announced a major expansion of its companion diagnostics (CDx) capabilities, positioning the company at the forefront of precision medicine innovation ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Building on its deep expertise in quantitative biomarker analysis and cutting-edge AI, Indica Labs’ new CDx offering is designed to accelerate drug development and support AI-powered companion diagnostics. The enhanced portfolio leverages the company’s robust digital pathology ecosystem to deliver scalable, reproducible, and compliant solutions to pharma partners worldwide.

Precision Medicine Team to Drive CDx Development

To advance companion diagnostics development, Doug Bowman will lead the newly formed Precision Medicine team at Indica Labs. Doug brings nine years of experience as the lead executive of the Pharma Services team at Indica Labs as well as a wealth of knowledge on biomarker assays through every stage of development – from discovery to clinical. The Precision Medicine team combines biomarker assay support expertise with deep AI diagnostics development expertise and together the team can support all stages of CDx development.

“Indica Labs is committed to transforming precision medicine with AI-enabled solutions that support every stage of biomarker discovery, validation, and clinical deployment,” said Doug Bowman, VP of Precision Medicine at Indica Labs. “Our expanded companion diagnostics offering provides a seamless path from research through regulatory submission, enabling sponsors to more rapidly and confidently bring targeted therapies to patients.”

AI-Driven Insights for Precision Medicine

Central to the new CDx offering is the deployment of advanced AI models integrated into Indica Labs’ HALO® digital pathology platforms, providing automated tissue classification, subcellular localization, phenotypic profiling, and quantitative continuous scoring. These capabilities generate rich cell-by-cell data that help sponsors identify and validate biomarkers with unprecedented depth and accuracy.

Indica’s offering also supports complex workflows including antibody-drug conjugate (ADC) analysis and multiplexed immunohistochemistry, enabling detailed spatial and phenotypic insights that inform therapeutic strategy and dosage optimization.

Seamless Integration with Global Development Programs

Indica Labs’ CDx development framework is underpinned by the same regulatory workflows and quality systems that are currently deployed for its diagnostic products, supporting compliance with ISO standards and regulatory frameworks including CE-IVDR and FDA premarket authorization. Its HALO AP® platform is already widely deployed by integrated delivery networks, academic medical centers, clinical labs, CROs, and pharma partners, providing a foundation for smooth transition of CDx assets from investigational use to global implementation.

The offering is strengthened through partnership with Leica Biosystems, enhancing Indica Labs’ ability to deliver seamless, end-to-end CDx co-development. By combining Indica Labs’ deep expertise in AI and biomarker analysis with Leica Biosystems’ broad portfolio of healthcare solutions and commercialization experience, the companies deliver comprehensive companion diagnostics development.

Schedule a Meeting at ASCO 2026

Pharma partners interested in exploring CDx collaboration opportunities are encouraged to schedule a meeting during ASCO 2026 with Doug Bowman, VP of Precision Medicine.

Regulatory

​HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP® is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition, HALO AP® provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR.​ PRR-MAR-000010v1

About Indica Labs

Indica Labs, the global leader in AI-powered digital pathology, is redefining medicine with pathology platforms supporting life science discovery, translational research, clinical workflows, and companion diagnostic development. HALO platforms integrate image management and quantitative image analysis to deliver standardized, reproducible tissue-based analysis at every stage of the translational journey.

Media Contact 

Jenna Karpel

jkarpel@indicalab.com